KDM4A and cancer: This newly revealed PTEN-independent mode of mTORC1/2 activation via the mutated IDH/2HG/KDM4A/DEPTOR pathway may provide an additional molecular mechanism to explain the oncogenic activity of IDH1/2 mutations in glioma and other cancers.